专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07232460B2 Nanodevices, microdevices and sensors on in-vivo structures and method for the same 失效
标题翻译：纳米器件，微型器件和传感器的体内结构及方法相同
公开(公告)号：US07232460B2
公开(公告)日：2007-06-19
申请号：US10132555
申请日：2002-04-25
申请人： Julian Van Erlach , Arlen L. Olsen , Jeffrey M. Smith , Laura B. Smith , Gerald E. Bender , Audra L. Stinchcomb , Denis P. Donnelly , James E. Peterson , Roger D. Whitmer , Gerald F. Dudding , Mark D. Scott
发明人： Julian Van Erlach , Arlen L. Olsen , Jeffrey M. Smith , Laura B. Smith , Gerald E. Bender , Audra L. Stinchcomb , Denis P. Donnelly , James E. Peterson , Roger D. Whitmer , Gerald F. Dudding , Mark D. Scott
IPC分类号： A61F2/06 , A61B5/00
CPC分类号： A61F2/82 , A61B5/0031 , A61B5/0084 , A61B5/02007 , A61B5/0215 , A61B5/05 , A61B5/0538 , A61B5/07 , A61B5/14546 , A61B5/1459 , A61B5/411 , A61B5/4839 , A61B5/6862 , A61B5/6876 , A61B2562/0285 , A61N1/05
摘要： An in-vivo method and apparatus is disclosed that comprises at least one sensor for determining changes in a human's an animal's body and reporting said changes outside the body. The sensor may be embedded in a sheath. The apparatus may be used to monitor chemical or physical changes in the body fluids. Alternatively, the apparatus may be used to monitor and regulate chemical or physical levels in humans and animals.
摘要翻译：公开了一种体内方法和装置，其包括至少一个传感器，用于确定人类动物体内的变化并报告身体外部的变化。传感器可以嵌入护套中。该装置可用于监测体液中的化学或物理变化。或者，该装置可用于监测和调节人和动物中的化学或物理水平。

2. 发明授权

US10022366B2 Extending and maintaining micropore viability of microneedle treated skin with lipid biosynthesis inhibitors for sustained drug delivery 有权
公开(公告)号：US10022366B2
公开(公告)日：2018-07-17
申请号：US14786698
申请日：2014-04-23
申请人： Audra L. Stinchcomb , Priyanka Ghosh
发明人： Audra L. Stinchcomb , Priyanka Ghosh
IPC分类号： A61K31/44 , A61K31/485 , A61K31/135 , A61K31/341 , A61K31/405 , A61K9/00
摘要： Microneedles and their use as a physical skin permeation enhancement technique facilitate drug delivery across the skin in therapeutically relevant concentrations. Micropores created in the skin by MNs reseal because of normal healing processes of the skin, thus limiting the duration of the drug delivery window. Pore lifetime enhancement strategies can increase effectiveness of MNs as a drug delivery mechanism by prolonging the delivery window. Fluvastatin (FLU) was used to enhance pore lifetime by inhibiting the synthesis of cholesterol, a major component of the stratum corneum lipids. The skin recovered within a 30-45-min time period following the removal of occlusion, and there was no significant irritation observed due to the treatment compared to the control sites. Thus, it can be concluded that localized skin treatment with FLU can be used to extend micropore lifetime and deliver drugs for up to 7 days across MN-treated skin.

3. 发明申请

US20090017102A1 Enhancing transdermal delivery of opiod antagonists and agonistis using codrugs links to bupropion or hydroxybupropion 有权
标题翻译：通过使用与安非他酮或羟基安非他酮联系的药物来增强阿片类药物拮抗剂和激动剂的透皮输送
公开(公告)号：US20090017102A1
公开(公告)日：2009-01-15
申请号：US11907954
申请日：2007-10-18
申请人： Audra L. Stinchcomb , Peter A. Crooks , Mohamed O. Hamad , Paul K. Kiptoo
发明人： Audra L. Stinchcomb , Peter A. Crooks , Mohamed O. Hamad , Paul K. Kiptoo
IPC分类号： A61K31/485 , C07C225/16 , C07D489/00 , A61P25/30 , A61K9/70 , A61K31/135
CPC分类号： A61K9/7084 , A61K31/135 , A61K31/485 , A61K47/36 , C07D489/08 , A61K2300/00
摘要： The present invention is directed to novel codrugs comprising bupropion or hydroxybupropion and an opioid antagonist or an opioid agonist joined together by chemical bonding. The codrugs provide a significant increase in the transdermal flux across human skin, as compared to the basic opioid antagonist or opioid agonist.
摘要翻译：本发明涉及包含安非他酮或羟基安非他丁的新型药物，以及通过化学键合连接在一起的阿片样物质拮抗剂或阿片样因子激动剂。与基本的阿片样物质拮抗剂或阿片样物质激动剂相比，该药物提供了穿过人体皮肤的透皮通量显着增加。

4. 发明申请

US20120034293A1 TRANSDERMAL DELIVERY OF CANNABINOIDS 审中-公开
标题翻译： CANNABINOIDS的转运
公开(公告)号：US20120034293A1
公开(公告)日：2012-02-09
申请号：US13271338
申请日：2011-10-12
申请人： Audra L. Stinchcomb , Buchi N. Nalluri
发明人： Audra L. Stinchcomb , Buchi N. Nalluri
IPC分类号： A61K9/70 , A61K31/05 , A61K31/435 , A61P25/04 , A61K31/536 , A61P1/14 , A61P25/00 , A61K31/352 , A61K31/047
CPC分类号： A61K9/0014 , A61K9/7084 , A61K31/352 , A61K31/353 , A61K31/473 , A61K31/485 , A61K47/10 , A61K47/12 , A61K47/14 , A61K2300/00
摘要： The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient. A first aspect of the invention provides a method for relieving symptoms associated with illness or associated with the treatment of illness in a mammalian subject, comprising the steps of selecting at least one cannabinoid from the group consisting of cannabinol, cannabidiol, nabilone, levonantradol, (−)-HU-210, (+)-HU-210, 11-hydroxy-Δ9-THC, Δ8-THC-11-oic acid, CP 55,940, and R(+)-WIN 55,212-2, selecting at least one permeation enhancer from the group consisting of propylene glycol monolaurate, diethylene glycol monoethyl ether, an oleoyl macrogolglyceride, a caprylocaproyl macrogolglyceride, and an oleyl alcohol, and delivering the selected cannabinoid and permeation enhancer transdermally to treat an illness.
摘要翻译：本发明通过经皮递送大麻素来克服与现有药物递送系统相关的问题。优选地，大麻素通过闭塞体（即贴片）递送以减轻有害的副作用并避免患者的药物的消化道（首过）代谢。本发明的第一方面提供了一种减轻与疾病相关的症状或与哺乳动物受试者的疾病的治疗相关的症状的方法，包括以下步骤：从大麻丙醇，大麻二醇，萘匹定，左旋他丹（以下称为）中选择至少一种大麻素 - ） - HU-210，（+） - HU-210,11-羟基 - 和Dgr; 9-THC，＆Dgr; 8-THC-11-酸，CP 55,940和R（+） - WIN 55,212-2，从由丙二醇单月桂酸酯，二甘醇单乙醚，油酰基聚乙二醇甘油酯，辛酰基己基甘草聚糖甘油酯和油醇组成的组中选择至少一种渗透促进剂，并经皮递送选择的大麻素和渗透促进剂以治疗疾病。

5. 发明授权

US08449908B2 Transdermal delivery of cannabidiol 有权
标题翻译：经皮递送大麻二醇
公开(公告)号：US08449908B2
公开(公告)日：2013-05-28
申请号：US11157034
申请日：2005-06-20
申请人： Audra L. Stinchcomb , Buchi N. Nalluri
发明人： Audra L. Stinchcomb , Buchi N. Nalluri
IPC分类号： A61F13/00 , A61F13/02 , A61K9/70 , A61L15/16
CPC分类号： A61K9/0014 , A61K9/7084 , A61K31/352 , A61K31/353 , A61K31/473 , A61K31/485 , A61K47/10 , A61K47/12 , A61K47/14 , A61K2300/00
摘要： The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient. A first aspect of the invention provides a method for relieving symptoms associated with illness or associated with the treatment of illness in a mammalian subject, comprising the steps of selecting at least one cannabinoid from the group consisting of cannabinol, cannabidiol, nabilone, levonantradol, (−)-HU-210, (+)-HU-210, 11-hydroxy-Δ9-THC, Δ8-THC-11-oic acid, CP 55,940, and R(+)-WIN 55,212-2, selecting at least one permeation enhancer from the group consisting of propylene glycol monolaurate, diethylene glycol monoethyl ether, an oleoyl macrogolglyceride, a caprylocaproyl macrogolglyceride, and an oleyl alcohol, and delivering the selected cannabinoid and permeation enhancer transdermally to treat an illness.
摘要翻译：本发明通过经皮递送大麻素来克服与现有药物递送系统相关的问题。优选地，大麻素通过闭塞体（即贴片）递送以减轻有害的副作用并避免患者的药物的消化道（首过）代谢。本发明的第一方面提供了一种减轻与疾病相关的症状或与哺乳动物受试者的疾病的治疗相关的症状的方法，包括以下步骤：从大麻丙醇，大麻二醇，萘匹定，左旋他丹（以下称为）中选择至少一种大麻素 - ） - HU-210，（+） - HU-210,11-羟基-Δ9-THC，Delta8-THC-11-酸，CP55,940和R（+） - WIN55,212-2，选择至少一种渗透促进剂来自由丙二醇单月桂酸酯，二甘醇单乙醚，油酰基聚乙二醇甘油酯，辛酰基己基甘草聚糖甘油酯和油醇组成的组，并经皮递送选择的大麻素和渗透促进剂以治疗疾病。

6. 发明申请

US20120202892A1 Cannabinoid-Containing Compositions and Methods for Their Use 审中-公开
标题翻译：含大麻素的组合物及其使用方法
公开(公告)号：US20120202892A1
公开(公告)日：2012-08-09
申请号：US13451666
申请日：2012-04-20
申请人： Audra L. Stinchcomb , Stan Lee Banks
发明人： Audra L. Stinchcomb , Stan Lee Banks
IPC分类号： A61K31/05 , A61P19/02 , A61P29/00
CPC分类号： A61K31/05 , A61K9/0014 , A61K9/06 , A61K31/352 , A61K47/14 , A61K47/32 , A61K2300/00
摘要： This invention relates to cannabinoid-containing compositions, particularly cannabinoid-containing gel formulations and methods for the treatment of traumatic injury, e.g., strains, sprains and contusions, and disease conditions, e.g., arthritis, particularly osteoarthritis. The methods involve topically applying a cannabinoid or a cannabinoid-containing composition to a subject's skin near, or distant from, the area of the injury or the area affected by the disease condition, e.g., an arthritic joint. The cannabinoid-containing composition is preferably a pharmaceutically acceptable gel containing a therapeutically effective amount of a cannabinoid sufficient to alleviate the symptoms associate with the injury or disease condition.
摘要翻译：本发明涉及含大麻素的组合物，特别是含大麻素的凝胶制剂和用于治疗创伤性损伤的方法，例如菌株，扭伤和挫伤，以及疾病状况，例如关节炎，特别是骨关节炎。所述方法涉及将大麻素或含大麻素的组合物局部施用于受伤区域或受疾病状况影响的区域（例如关节炎关节）附近或远离受试者的皮肤。含大麻素的组合物优选是含有治疗有效量的大麻素的药学上可接受的凝胶，其足以减轻与损伤或疾病状况相关的症状。

7. 发明授权

US08653271B2 Enhancing transdermal delivery of opioid antagonists and agonists using codrugs linked to bupropion or hydroxybupropion 有权
标题翻译：使用与安非他酮或羟基安非他酮相联系的药物增强阿片样物质拮抗剂和激动剂的透皮递送
公开(公告)号：US08653271B2
公开(公告)日：2014-02-18
申请号：US11907954
申请日：2007-10-18
申请人： Audra L. Stinchcomb , Peter A. Crooks , Mohamed O. Hamad , Paul K. Kiptoo
发明人： Audra L. Stinchcomb , Peter A. Crooks , Mohamed O. Hamad , Paul K. Kiptoo
IPC分类号： C07D489/00 , C07D489/02 , C07D489/12 , A61K31/485
CPC分类号： A61K9/7084 , A61K31/135 , A61K31/485 , A61K47/36 , C07D489/08 , A61K2300/00
摘要： The present invention is directed to novel codrugs comprising bupropion or hydroxybupropion and an opioid antagonist or an opioid agonist joined together by chemical bonding. The codrugs provide a significant increase in the transdermal flux across human skin, as compared to the basic opioid antagonist or opioid agonist.
摘要翻译：本发明涉及包含安非他酮或羟基安非他丁的新型药物，以及通过化学键合连接在一起的阿片样物质拮抗剂或阿片样因子激动剂。与基本的阿片样物质拮抗剂或阿片样物质激动剂相比，该药物提供了穿过人体皮肤的透皮通量显着增加。

8. 发明授权

US08435556B2 Transdermal delivery of cannabidiol 有权
公开(公告)号：US08435556B2
公开(公告)日：2013-05-07
申请号：US12511226
申请日：2009-07-29
申请人： Audra L. Stinchcomb , Buchi N. Nalluri
发明人： Audra L. Stinchcomb , Buchi N. Nalluri
IPC分类号： A61F13/00 , A61F13/02 , A61K9/70 , A61L15/16
CPC分类号： A61K9/0014 , A61K9/7084 , A61K31/352 , A61K31/353 , A61K31/473 , A61K31/485 , A61K47/10 , A61K47/12 , A61K47/14 , A61K2300/00
摘要： The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient. A first aspect of the invention provides a method for relieving symptoms associated with illness or associated with the treatment of illness in a mammalian subject, comprising the steps of selecting at least one cannabinoid from the group consisting of cannabinol, cannabidiol, nabilone, levonantradol, (−)-HU-210, (+)-HU-210, 11-hydroxy-Δ9-THC, Δ8-THC-11-oic acid, CP 55,940, and R(+)-WIN 55,212-2, selecting at least one permeation enhancer from the group consisting of propylene glycol monolaurate, diethylene glycol monoethyl ether, an oleoyl macrogolglyceride, a caprylocaproyl macrogolglyceride, and an oleyl alcohol, and delivering the selected cannabinoid and permeation enhancer transdermally to treat an illness.

9. 发明申请

US20120202891A1 Cannabinoid-Containing Compositions and Methods for Their Use 审中-公开
公开(公告)号：US20120202891A1
公开(公告)日：2012-08-09
申请号：US13318208
申请日：2009-04-29
申请人： Audra L. Stinchcomb , Stan Lee Banks
发明人： Audra L. Stinchcomb , Stan Lee Banks
IPC分类号： A61K31/05 , A61P19/02
CPC分类号： A61K9/0014 , A61K47/08 , A61K47/10
摘要： This invention relates to cannabinoid-containing compositions, particularly cannabinoid-containing gel formulations and methods for the treatment of traumatic injury, e.g., strains, sprains and contusions, and disease conditions, e.g., arthritis, particularly osteoarthritis. The methods involve topically applying a cannabinoid or a cannabinoid-containing composition to a subject's skin near, or distant from, the area of the injury or the area affected by the disease condition, e.g., an arthritic joint. The cannabinoid-containing composition is preferably a pharmaceutically acceptable gel containing a therapeutically effective amount of a cannabinoid sufficient to alleviate the symptoms associate with the injury or disease condition.

10. 发明申请

US20090291128A1 TRANSDERMAL DELIVERY OF CANNABINOIDS 有权
标题翻译： CANNABINOIDS的转运
公开(公告)号：US20090291128A1
公开(公告)日：2009-11-26
申请号：US12511226
申请日：2009-07-29
申请人： Audra L. Stinchcomb , Buchi N. Nalluri
发明人： Audra L. Stinchcomb , Buchi N. Nalluri
IPC分类号： A61K9/70 , A61K31/352 , A61K31/055 , A61K31/473 , A61P35/00 , A61P29/00
CPC分类号： A61K9/0014 , A61K9/7084 , A61K31/352 , A61K31/353 , A61K31/473 , A61K31/485 , A61K47/10 , A61K47/12 , A61K47/14 , A61K2300/00
摘要： The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient. A first aspect of the invention provides a method for relieving symptoms associated with illness or associated with the treatment of illness in a mammalian subject, comprising the steps of selecting at least one cannabinoid from the group consisting of cannabinol, cannabidiol, nabilone, levonantradol, (−)-HU-210, (+)-HU-210, 11-hydroxy-Δ9-THC, Δ8-THC-11-oic acid, CP 55,940, and R(+)-WIN 55,212-2, selecting at least one permeation enhancer from the group consisting of propylene glycol monolaurate, diethylene glycol monoethyl ether, an oleoyl macrogolglyceride, a caprylocaproyl macrogolglyceride, and an oleyl alcohol, and delivering the selected cannabinoid and permeation enhancer transdermally to treat an illness.
摘要翻译：本发明通过经皮递送大麻素来克服与现有药物递送系统相关的问题。优选地，大麻素通过闭塞体（即贴片）递送以减轻有害的副作用并避免患者的药物的消化道（首过）代谢。本发明的第一方面提供了一种减轻与疾病相关的症状或与哺乳动物受试者的疾病的治疗相关的症状的方法，包括以下步骤：从大麻丙醇，大麻二醇，萘匹定，左旋他丹（以下称为）中选择至少一种大麻素 - ） - HU-210，（+） - HU-210,11-羟基-Δ9-THC，Delta8-THC-11-酸，CP55,940和R（+） - WIN55,212-2，选择至少一种渗透促进剂来自由丙二醇单月桂酸酯，二甘醇单乙醚，油酰基聚乙二醇甘油酯，辛酰基己基甘草聚糖甘油酯和油醇组成的组，并经皮递送选择的大麻素和渗透促进剂以治疗疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式